Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil after DWEK
NCT04057053Phase 1Completed
- Sponsor
- Massachusetts Eye and Ear
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of netarsudil in Fuchs endothelial dystrophy (FED) (2 arms), sponsored by Massachusetts Eye and Ear. Primary endpoint: Time to corneal clearance at 6 months. Started Oct 2018; status: completed.
02
Drugs
netarsudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT04057053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057053.